2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|September 17, 2018
Aptar Pharma to Host Drug Delivery Insight Briefing at CPhI 2018
Author(s)Pharmaceutical Technology Editors
Guenter Nadler, director of Business Development at Aptar Pharma, will present an insight briefing on new drug-delivery trends in treating upper and lower respiratory tract issues on Wednesday, Oct. 9, 2018 at CPhI Worldwide.
Advertisement
Guenter Nadler, director of business development at Aptar Pharma, will present an insight briefing on new trends in treating upper and lower respiratory tract issues, including new respiratory technology platforms designed to market needs, on Tuesday, Oct. 9, 2018 in Madrid, Spain at CPhI Worldwide.
The discussion, “Portable Care for Your Respiratory Tract: Exploring New Technology Platforms,” will explore the necessity for more modern, portable treatments and offer insight into how to deliver such solutions to clients. Nadler’s briefing will take place at 12:30–1:00pm at InnoPack & P-MEC Theatre, Hall 4, stand 4F121.
As part of Aptar Pharma’s Consumer Health Care division, Nadler heads strategy and innovation for the company’s Cough & Cold business. He has 18 years of experience in drug delivery, including various technical and commercial roles.
Source:
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5